D011758Chemicals & DrugsD03.383.129.578621840.890788Pyrrolesplugins:TwitterTwitterprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson30995068He L, Du J, Chen Y, Liu C, Zhou M, Adhikari S, Rubin DT, Pekow J, Li YCAmerican journal of physiology. Gastrointestinal and liver physiologyRenin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway. Am J Physiol Gastrointest Liver Physiol. 2019 06 01; 316(6):G774-G784.Am J Physiol Gastrointest Liver Physiol2019-04-17T00:00:002019Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway.30997845Gomez-Arteaga A, Margolskee E, Wei MT, van Besien K, Inghirami G, Horwitz SLeukemia & lymphomaCombined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019 07; 60(7):1626-1631.Leuk Lymphoma2019-04-18T00:00:002019Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.32203698Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, FĂ©liz L, Vogel AThe Lancet. OncologyPemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 05; 21(5):671-684.Lancet Oncol2020-03-20T00:00:002020Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.32513564Hamilton E, O'Malley DM, O'Cearbhaill R, Cristea M, Fleming GF, Tariq B, Fong A, French D, Rossi M, Brickman D, Moore KGynecologic oncologyTamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.Gynecol Oncol2020-06-06T00:00:002020Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.32029634Piperno-Neumann S, Larkin J, Carvajal RD, Luke JJ, Schwartz GK, Hodi FS, Sablin MP, Shoushtari AN, Szpakowski S, Chowdhury NR, Brannon AR, Ramkumar T, de Koning L, Derti A, Emery C, Yerramilli-Rao P, Kapiteijn EMolecular cancer therapeuticsGenomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Mol Cancer Ther. 2020 04; 19(4):1031-1039.Mol Cancer Ther2020-02-06T00:00:002020Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.3.86170.014171862research area of0.7679930.0408026193subject area forhttps://rubinlab.uchicago.edu/Rubin Lab Sitehttps://www.uchicagomedicine.org/conditions-services/inflammatory-bowel-diseaseInflammatory Bowel Disease CenterIBDMDMedicineUniversity of ChicagoLarryGoldsteinLarry Goldstein41.78927490000000-87.601250000000001509Goldstein, LarryWalter M.StadlerWalter M. Stadler41.78927490000000-87.601250000000001904Stadler, Walter M.ProfessorEverett E.VokesEverett E. Vokes41.78927490000000-87.601250000000001920Vokes, Everett E.ProfessorDavid T.RubinDavid T. Rubin41.78927490000000-87.60125000000000256Rubin, David T.ProfessorMichael H.DavidsonMichael H. Davidson41.78927490000000-87.60125000000000611Davidson, Michael H.Clinical Professortrue1true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Clinical ProfessorClinical ProfessorMedicine-Cardiology